Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

3.79
-0.1200-3.07%
Post-market: 3.790.00000.00%19:30 EDT
Volume:502.50K
Turnover:1.90M
Market Cap:301.85M
PE:-5.28
High:3.94
Open:3.90
Low:3.59
Close:3.91
52wk High:6.83
52wk Low:1.15
Shares:79.64M
Float Shares:4.56M
Volume Ratio:0.83
T/O Rate:11.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7183
EPS(LYR):-1.2929
ROE:-57.73%
ROA:-27.15%
PB:2.26
PE(LYR):-2.93

Loading ...

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

TIPRANKS
·
Jul 28

Prelude Therapeutics Shareholders Back Leadership and Governance

TIPRANKS
·
Jun 11

Prelude Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 11

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
May 15

Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 14

Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

TIPRANKS
·
May 12

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Benzinga Earnings
·
May 12

Prelude Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 12

BRIEF-Prelude Therapeutics Q1 EPS USD -0.13

Reuters
·
May 12

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 12

Prelude Therapeutics Q1 Operating Expenses USD 18.757 Million

THOMSON REUTERS
·
May 12

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 08

Prelude Therapeutics Initiated at Buy by D. Boral Capital

Dow Jones
·
May 04

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

TIPRANKS
·
May 03

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 01

Prelude Therapeutics initial beneficial ownership statement names RA Capital Management

Reuters
·
Apr 29

Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 27

Prelude Therapeutics Incorporated : H.c. Wainwright Raises Target Price to $8 From $5

THOMSON REUTERS
·
Apr 27

Massive Insider Buying Spree Signals Bold Confidence in Prelude Therapeutics

TIPRANKS
·
Apr 24